NEW YORK (GenomeWeb News) – Life Technologies has filed a suit asking a federal court to find that the firm does not infringe a patent held by Promega and it has retained rights under a licensing agreement related to cell line authentication and identification.

Life Tech also asked the US District Court Southern District of California to find that the dispute should be resolved through binding arbitration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.